Joshua Jennings

Answer

EVP & President of Diabetes Que Dallara confirmed the U.S. slowdown is a timing issue as patients await new CGMs, with production ramping significantly to meet demand. She stated the Abbott-based Instinct sensor is expected to launch 'in the coming months.' EVP & CFO Thierry Piéton added that the planned separation of the business remains on track for completion within 15 months.

Ask Fintool Equity Research AI

Answer

CEO Geoff Martha noted the recent U.S. National Coverage Analysis (NCA) milestone will create a global 'halo effect.' Sean Salmon, EVP & President of the Cardiovascular Portfolio, detailed the international strategy, explaining it's a country-by-country process. He cited progress with reimbursement in France and recent approval in China, with Japan being the main outstanding market. However, he emphasized the U.S. will be the dominant growth driver for RDN.

Ask Fintool Equity Research AI

Answer

CEO & Co-Chairman Paul LaViolette confirmed that for the competitive and capital-intensive catheter-based EP market, the company's strategy is to pursue a partnership and that discussions are ongoing. He stated that the platform is already compatible with leading mapping systems and that integration can be deepened through collaboration. LaViolette emphasized that nSPFA's rapid procedure times and low neuromuscular stimulation make it exceptionally well-suited for the ASC setting.

Ask Fintool Equity Research AI

Answer

CEO Paul LaViolette confirmed that the company's strategy for the catheter-based EP market is to pursue a partnership and that discussions are underway. Regarding mapping systems, he noted that the platform is already compatible with leading systems and that deeper, more customized integration is possible over time with partners. LaViolette highlighted that the platform's rapid procedure times and low neuromuscular stimulation make it very well-suited for the ASC setting.

Ask Fintool Equity Research AI

Answer

CEO Peter Caldini clarified the U.S. strategy is to launch Preservay first in 2026, followed by Mia after its regulatory approval. He emphasized that the current early experience program for Preservay is for learning and is not expected to have a significant revenue impact in 2025, nor is it a material component of the updated guidance.

Ask Fintool Equity Research AI

Answer

CEO Peter Caldini attributed the strong U.S. launch to a superior product and effective marketing, stating that while performance is exceeding expectations, the company is choosing to remain conservative with its guidance. He noted that the competitive response has not been significant, with only isolated instances of price discounting after clinics had already converted to Motiva.

Ask Fintool Equity Research AI

Answer

Executive Rajbir Denhoy and CEO Juan Jose Quiros confirmed the strength of the Mia data, which shows a near-elimination of device and technique-related complications. They stated that the company is preparing for discussions with the FDA regarding the regulatory pathway for both Mia and the Ergonomix2 platform, with the goal of leveraging this compelling global data.

Ask Fintool Equity Research AI

Answer

CEO Jane Chao explained that the economic value for delirium is expected to parallel the seizure indication, primarily by reducing hospital length of stay, a key metric for DRG-reimbursed patients. CFO Scott Blumberg addressed pricing, stating that headband prices have been relatively consistent, while the average selling price for the Clarity subscription has increased over time as more recorders are added to subscriptions.

Ask Fintool Equity Research AI

Answer

CEO Xingjuan Chao quantified the opportunity by stating Ceribell is only 20-30% penetrated within its existing accounts, leaving a 70% growth opportunity. She confirmed the hub-and-spoke model is a key and effective strategy. Regarding competition, she asserted that Ceribell remains the clear category leader with unmatched technology and clinical evidence, and is not seeing a meaningful impact from emerging competitors.

Ask Fintool Equity Research AI

Answer

CEO Xingjuan Chao reiterated that Ceribell has only penetrated about 3% of the total U.S. market, which includes a 70% opportunity for growth within existing accounts by expanding across departments. She confirmed the hub-and-spoke expansion model is a key strategy. Regarding competition, she stated that while some companies are trying to enter the point-of-care EEG category, Ceribell remains the clear leader and is not seeing a meaningful competitive impact on its business.

Ask Fintool Equity Research AI

Answer

CEO Jane Chao explained that based on pre-submission discussions, the FDA's key requirement for the delirium indication is demonstrating the algorithm's accuracy is comparable to the CAM-ICU nursing assessment. She elaborated that the 'new vital sign' vision involves creating synergies between indications like seizure, stroke, and delirium to help clinicians differentiate neurological conditions in the same patient population and call points, thereby expanding the market.

Ask Fintool Equity Research AI

Answer

CEO Jane Chao explained that for the delirium submission, the FDA's core metric is the algorithm's accuracy compared to the current standard of care. She elaborated on the 'new vital sign' strategy, stating that indications for seizure, delirium, and stroke are synergistic. They address the key conditions physicians must differentiate in patients with altered mental status, targeting the same call points and patient populations to provide a more complete neurological assessment.

Ask Fintool Equity Research AI

Answer

CEO Xingjuan Chao confirmed that the platform's economic impact is a major sales driver, with different benefits like reduced patient transfers or improved ICU capacity management resonating with different types of hospitals. She stated that 100% of new accounts adopt the AI algorithm (Clarity or ClarityPro). While ClarityPro offers stronger clinical benefits, the company is still in the process of driving its adoption, as it involves additional fees and the NTAP program is only a year old.

Ask Fintool Equity Research AI

Answer

Executive Xingjuan Chao confirmed that economic benefits are a major adoption driver and that different value propositions resonate with different hospitals. She noted that 100% of new accounts use their AI algorithm and that while ClarityPro offers stronger clinical benefits, the company is still in the process of driving its adoption.

Ask Fintool Equity Research AI

Answer

President, CEO & Chairman Joseph Devivo clarified that the guidance revision was due to delays in closing large enterprise and medical school deals, not competitive headwinds. He explained that Butterfly is pioneering this market segment. For software, he noted a 'tale of two stories': churn in individual subscriptions is a headwind, while enterprise software revenue is growing. He positioned the upcoming Compass AI platform as a 'generational shift' that will simplify documentation and automation, making it a key catalyst for both software and overall enterprise sales.

Ask Fintool Equity Research AI

Answer

CEO Joseph DeVivo described the Rochester publication as a 'seminal moment' that enabled C-suite conversations by proving clinical and economic value. CFO Heather Getz added that iQ3 adoption is strong across all channels, not just hospitals, and confirmed the company has 'virtually no foreign currency risk,' with potential tariff impacts being manageable.

Ask Fintool Equity Research AI

Answer

Joseph DeVivo, Chairman and CEO, affirmed high confidence in the long-term target, stating the company is on track with its 5-year plan. He highlighted the significant upside from the Octiv and HomeCare initiatives, noting the HomeCare pilot is proving the model's scalability by training partners' existing staff. DeVivo explained that the wearable device development is being deliberately paced to align with the market use case currently being established through the HomeCare pilot, ensuring demand exists before the product launch.

Ask Fintool Equity Research AI

Answer

Joseph DeVivo, Chairman and CEO, attributed the strong U.S. launch to a desirable product and effective execution across all channels, including e-commerce, inside sales, and direct sales. On the RoHS directive, he described a productive meeting with EU officials and outlined the timeline for a potential revocation of exemptions for competitors, expecting a decision by late 2025. Regarding the iQ Station, DeVivo positioned it as a revolutionary workstation powered by the future P5 chip, designed to completely reimagine in-facility imaging workflows rather than being a simple cart.

Ask Fintool Equity Research AI

Answer

Chairman & CEO Pat Miles explained that while the lateral franchise is often the entry point, a significant halo effect is driving growth in areas like deformity, informed by the EOS ecosystem. He noted that market share is substantially higher where EOS systems are installed and that interest from academic institutions is at an all-time high. CFO Todd Koning added that the company is attracting a broader base of surgeons.

Ask Fintool Equity Research AI

Answer

CEO Dominick Colangelo outlined the MACI Ankle trial as a Phase III study enrolling approximately 300 patients with a 2-year endpoint, comparing MACI to microfracture. CFO Joe Mara reaffirmed that the company's long-term targets for high 70s% gross margin and high 30s% adjusted EBITDA margin by 2029 remain on track, supported by strong current performance.

Ask Fintool Equity Research AI

Answer

CEO Nick Colangelo reported that while formal data is pending from a patient registry, anecdotal surgeon feedback on MACI Arthro has been positive, indicating better post-operative recovery as expected from a less invasive procedure. He also noted the learning curve is not steep. Regarding the sales force expansion, Nick Colangelo stated it's a targeted effort to support growth in high-volume areas. CFO Joe Mara added that the associated costs are factored into the full-year guidance and will be incurred in the second half, not impeding the strong margin ramp driven by higher revenue.

Ask Fintool Equity Research AI

Answer

CFO Joe Mara stated that significant outperformance in 2024, with gross margin reaching 73% and 78% in Q4, provided the confidence to update the long-term targets. He acknowledged the path to the 2029 goals might not be perfectly linear as the new facility's costs are absorbed, but the overall trajectory of ~1 point/year for gross margin and ~3 points/year for adjusted EBITDA margin remains the expectation.

Ask Fintool Equity Research AI

Answer

CEO Nick Colangelo explained that reps began discussing the Arthro option for existing unconverted biopsies only after approval. He confirmed a mid-to-high single-digit price increase for MACI is planned for 2025 and that disposable Arthro instruments generate a small amount of revenue. He also stated that the company will re-evaluate its sales force size in early 2025 to effectively target the expanded surgeon base.

Ask Fintool Equity Research AI

Answer

CEO Waleed Hassanein stated he sees no headwinds, as the NOP's success in growing transplant volume aligns with modernization goals. He emphasized a collaborative approach with OPOs. He also clarified that TransMedics is not currently engaged with CMS for trial reimbursement, as it is not deemed necessary for these technology modifications.

Ask Fintool Equity Research AI

Answer

Executive Waleed Hassanein confirmed there was a 'pretty loud' buzz for both the heart and lung trials at ISHLT, with significant interest from both U.S. and international surgeons. Regarding the heart trial's superiority endpoint, he emphasized that TransMedics is unique in pursuing Level 1 evidence against the standard of care and expressed confidence in their approach, stating they will let the rigorous trial data speak for itself.

Ask Fintool Equity Research AI

Answer

CEO Waleed Hassanein dismissed concerns of customer attrition as "confabulation" from the short report, confirming that the centers cited remain active users. Regarding competition, he stated that NRP is not mutually exclusive with OCS, as the organ still requires preservation and assessment post-NRP, and noted that TransMedics' market share in DCD liver actually increased.

Ask Fintool Equity Research AI

Answer

CEO Waleed Hassanein acknowledged they had forecasted headwinds but conceded the Q3 slowdown was slightly higher than anticipated, attributing it to summer seasonality across all three organs. He explicitly confirmed that TransMedics' market share in both liver and heart, at both the center and national levels, remained unchanged in Q3.

Ask Fintool Equity Research AI

Answer

CEO Kevin Sayer stated that relationships with key DME partners are now 'much stronger' and that the company is focused on maintaining sufficient inventory for them. He emphasized that the new commercial team is dedicated to these partnerships, which will be critical for navigating the upcoming CMS competitive bidding process.

Ask Fintool Equity Research AI

Answer

CEO Kevin Sayer noted that a significant volume shift to pharmacy has already occurred for commercial pump users, and Dexcom is well-positioned to serve that channel. CFO Jereme Sylvain added a key constraint: the Medicare Fee-for-Service population is reimbursed via Part B (DME), which limits how much of the total market can shift to pharmacy.

Ask Fintool Equity Research AI

Answer

Chairman and CEO Robert Ford reported that Navitor sales have doubled over the past two years, driven by international performance. He sees a significant opportunity to accelerate growth in Europe due to a competitor's market exit, timed well with Navitor's upcoming CE Mark for low/intermediate risk. In the U.S., Abbott is doubling its commercial team to expand its presence from 20% of centers and drive share gains into 2026.

Ask Fintool Equity Research AI

Answer

Chairman and CEO Robert Ford responded that while Abbott is actively engaged with industry association AdvaMed on tariffs, "hope is not a strategy," and the company is focused on operational mitigation. He strongly defended the diversified model, stating it provides strategic advantages and stability in uncertain environments. He affirmed that the current portfolio is creating value and that Abbott remains the best owner for its businesses, seeing no current need for divestitures.

Ask Fintool Equity Research AI

Answer

CEO Robert Ford confirmed that a 50-100 basis point annual improvement is the company's target model. He highlighted the Nutrition business as a significant opportunity for gross margin recovery as commodity costs normalize. He also praised the EPD (pharmaceuticals) team for successfully expanding margins despite significant FX headwinds. Ford noted that while gross margin is still recovering, the 2025 operating margin guidance is already ahead of pre-pandemic levels due to spending efficiencies.

Ask Fintool Equity Research AI

Answer

Robert Ford, Chairman and CEO, stated that he is not seeing or forecasting a capacity bottleneck and is not concerned about it becoming a rate-limiting factor. He believes that as demand grows, healthcare systems will make the necessary investments to expand capacity. He added that Abbott's focus is on investing in its own field presence to support the growth of its comprehensive structural heart portfolio.

Ask Fintool Equity Research AI

Answer

Shantanu Gaur, Founder and CEO, reported that the FDA was receptive to using alternative statistical methods to analyze the AUDACITY trial's control group data, which he believes will strengthen the PMA submission. He confirmed that clinicians are already organically combining the Allurion program with GLP-1s, providing real-world validation. Gaur anticipates a steady increase in revenue through 2025, driven by the onboarding of new sales team members and the global expansion of the new B2B2C strategy.

Ask Fintool Equity Research AI

Answer

Founder and CEO Shantanu Gaur confirmed that the first three PMA modules are under active FDA review with positive interactions, and the final clinical data module is expected early next year. He detailed that the VCS generates per-patient-per-month recurring revenue from providers managing patients on various weight loss therapies, including GLP-1s. Gaur stated that while the company is not providing 2025 guidance or a specific timeline for the French market's return, he believes the VCS has massive potential to accelerate top-line growth.

Ask Fintool Equity Research AI

Answer

CFO Dale Sander stated the company remains comfortable with previous guidance, expecting a second-half weighted revenue ramp. CEO Dr. Laura Niklason explained that for the V012 trial, key learnings involve closely monitoring post-implantation handling of the conduit. She also affirmed the Fresenius partnership remains strong, with Fresenius encouraged by V007 trial results and aligned on reducing patient catheter-dependency.

Ask Fintool Equity Research AI

Answer

Executive Laura Niklason explained that rapid Value Analysis Committee (VAC) approvals were driven by strong surgeon champions and a commitment to patient care at a mix of trial and non-trial sites. While declining to give formal guidance, she noted the current pace could see most Level 1 trauma centers initiating the VAC process by year-end, with sales weighted to the second half. She also clarified that the AV access indication is now expected to contribute to revenue in 2027, not 2026. Regarding the article, she stated that trial surgeons were 'incensed' by what they felt was biased reporting and have drafted a rebuttal.

Ask Fintool Equity Research AI

Answer

Executive Laura Niklason stated that discussions with Fresenius are ongoing and that while Fresenius leadership was encouraged by the data showing reduced catheter time, it's uncertain if the current results are sufficient to trigger the agreement. She confirmed ATEV's utility in revision cases for both aneurysmal fistulas and infected synthetic grafts. For the PAD indication, she noted it could be their largest market, but a Phase 3 trial is on hold pending an improved cash position, which could come from financing or a partnership.

Ask Fintool Equity Research AI

Answer

David Fischel (executive) explained that he expects the case mix to continue favoring complex procedures like VTs and PVCs, where robotic navigation provides the most value. For the EMAGIN neurovascular portfolio, he outlined that initial adoption could occur in existing labs, but broader adoption will likely be predicated on the availability of GenesisX and its compatibility with various X-ray systems, with initial sites being established to demonstrate clinical value.

Ask Fintool Equity Research AI

Answer

The initial U.S. indication for MAGIC will focus on patients with high unmet medical needs. The APT catheter portfolio is seeing a ramp-up through sales team education and securing hospital contracts, with an expected market opportunity in the high single-digit to double-digit millions. The robotic HD mapping catheter is planned for regulatory submission in Q1 2025 and is expected to significantly increase disposable revenue per procedure, potentially doubling it on top of the ablation catheter's contribution.

Ask Fintool Equity Research AI

Answer

The MAGiC study is performing well and data is being prepared for publication. The company is in collaborative discussions with the FDA to leverage European data for a US PMA submission, followed by post-approval studies. While the MAGiC catheter is capable of high-power ablation, the initial regulatory submission is for up to 50 watts. The magnetic VT study results are being prepared for presentation at an upcoming conference.

Ask Fintool Equity Research AI

Answer

Leslie Trigg, Chair and CEO, stated that Outset has not observed any changes in the hospital capital spending climate and that Tablo's value proposition is advantaged because it offers tangible, near-term economic savings with a short payback period, which is compelling in any environment. She confirmed that sales force attrition was at a record low in Q1 and that the team is currently rightsized. She noted that future investments will be focused on incrementally growing the field service team to support the expanding installed base, rather than the capital sales team.

Ask Fintool Equity Research AI

Answer

CEO Leslie Trigg stated that the sales transformation is progressing well, with key changes largely complete and expected to be fully settled in early 2025, though positive impacts were already seen in Q3. She confirmed that no deals exited the pipeline, the 9-12 month sales cycle for large deals is stable, and while TabloCart's return is helpful, the core value proposition of cost savings and improved care remains the primary sales driver.

Ask Fintool Equity Research AI

Answer

Executive Reza Zadno responded that while they could potentially obtain a tool claim, the primary strategic goal is to expand the prostate cancer market. To achieve this and influence treatment guidelines, the company is focused on generating Level 1 data through the WATER IV randomized controlled trial against radical prostatectomy.

Ask Fintool Equity Research AI

Answer

CEO Reza Zadno stated that competition is mainly in the non-resective space and that PROCEPT is unique in running an FDA randomized trial against radical prostatectomy. CCO Sham Shiblaq added that their primary resective competitor is the fragmented TURP market, which is an advantage. CFO Kevin Waters confirmed the 2025 guidance does not assume any revenue related to a prostate cancer indication.

Ask Fintool Equity Research AI

Answer

Executive Reza Zadno explained the WATER IV trial aims to generate Level 1 data to expand the prostate cancer market by demonstrating harm reduction. Executive Sham Shiblaq noted that surgeons already felt safe treating these patients and the label change affirmed this. Regarding ASCs, Shiblaq confirmed the pilot's success and plans for a deliberate, limited expansion in 2025, while maintaining a primary focus on the large hospital greenfield market.

Ask Fintool Equity Research AI

Answer

President and CEO Ivan Tornos stated that over 20% of U.S. sales now come from the ASC setting, a significant increase from pre-pandemic levels. He noted that Zimmer Biomet is the #1 reconstructive company for knees and hips in the ASC space and is well-positioned to grow above market. He added that the S.E.T. business is also performing well and is expected to accelerate.

Ask Fintool Equity Research AI

Answer

Chief Operating Officer Vivek Jayaraman attributed the strong North American growth to underlying demand in the U.S. for both platelets and IFC, noting continued share capture opportunities. He clarified that while Canada contributed, growth was predominantly from the U.S. Senior Vice President Carol Moore detailed the regulatory process for the red blood cell system, explaining that the notified body (TUV) conducts a clinical review first before advancing the file to competent authorities, and expressed confidence in the strength of the resubmitted application.

Ask Fintool Equity Research AI

Answer

Executive Vivek Jayaraman stated that the IFC market is inflecting, with momentum from AABB and recent BLA approvals unlocking demand. He emphasized that balancing supply with spiking demand and maturing clinical evidence are key to market penetration. Executive William Greenman addressed the China question, noting an expected NMPA approval this year, followed by a provincial reimbursement process of about a year. He clarified that meaningful revenue from China is not expected in 2025 but represents a significant long-term opportunity.

Ask Fintool Equity Research AI

Answer

COO Vivek Jayaraman confirmed more BLA applications are in process for 2025 and beyond, noting current capacity is sufficient to meet demand. CFO Kevin Green explained the LED illuminator is expected to be gross margin neutral with a higher ASP. President and CEO Obi Greenman added that the new system's IP significantly extends the company's competitive moat.

Ask Fintool Equity Research AI

Answer

CFO Leigh Vosseller confirmed that durable pumps are widely accepted in the pharmacy channel and that various reimbursement structures are possible. She specified that Tandem's current contracts are not subscription-based, so they do not anticipate the headwinds some competitors face with that model.

Ask Fintool Equity Research AI

Answer

CCO Mark Novara confirmed the FDA approval covers all insulin-using Type 2 patients, including basal-only. CFO Leigh Vosseller explained that commercial coverage is strong, but Medicare coverage still has onerous requirements. She noted Tandem is actively working with industry partners to advocate for changes to the national coverage determination with CMS.

Ask Fintool Equity Research AI

Answer

President and CEO John Sheridan stated that off-label use for Type 2 has remained steady at 5-10% of new starts and he doesn't expect a significant increase until after approval and active marketing. However, he revealed that recent market research indicates a higher propensity for adoption, leading them to believe market penetration could eventually exceed 25%, up from a previous estimate of 15%.

Ask Fintool Equity Research AI

Answer

Michael Mahoney, Chairman and CEO, stated that capacity is not currently a constraint, as the efficiency and strong reimbursement of these procedures are driving hospitals to invest in new labs. Dr. Ken Stein, CMO, added that Boston Scientific is enabling the shift to ASCs by making FARAPULSE safe, efficient, and predictable, with features that reduce the need for general anesthesia and expensive mapping catheters.

Ask Fintool Equity Research AI

Answer

CEO Mike Mahoney characterized the situation as a dynamic environment but stated that the company's guidance already accounts for global macro challenges, including tariffs, which he views as manageable. He expressed hope for an appropriate FTC environment and noted that historically, the medtech industry has not been a primary target of major policy changes across different administrations. Overall, he conveyed comfort in the company's ability to manage through potential policy shifts.

Ask Fintool Equity Research AI

Answer

CEO Michael Mahoney directly stated there are no supply issues and the team has done a great job scaling catheter and console supply. CMO Dr. Ken Stein clarified the FARAWAVE NAV is a single-use device and highlighted the Orion high-density mapping catheter. He noted future catheters like FARAPOINT and FARAFLEX will integrate mapping and ablation, further building out their portfolio to target arrhythmias.

Ask Fintool Equity Research AI

Answer

Barry Wolfenson, an executive, explained that collaborators like Solventum and Molnlycke provide standardized products and crucial training to minimize trial variability and optimize outcomes. He also confirmed the DFU study aims to mirror the VLU trial, with plans to approach the FDA and EMA in the second half of the year. CEO Ofer Gonen added that regulatory approvals for the new facility are anticipated in early 2026 from the EMA and mid-2026 from the FDA, contingent on required stability data.

Ask Fintool Equity Research AI

Answer

Ofer Gonen (Executive) clarified that the EscharEx Phase III protocol is cleared by the FDA and EMA, with an IND submission imminent and patient enrollment expected to begin 30 days after. He stated the head-to-head study is internally driven to bolster the commercial launch package, not a regulatory mandate. Regarding manufacturing, Gonen confirmed the new facility's construction is complete and is now in the pre-planned commissioning phase, with timing for full operation dependent on upcoming regulatory inspections.

Ask Fintool Equity Research AI

Answer

CEO Adam Sachs confirmed that ventral hernia repairs, including defect closure and mesh implantation, were successfully performed in the cadaver labs. He explained that the final clinical trial design will be locked in after the initial first-in-human cases, leveraging the flexibility of the FDA's Safer Technologies Program. President Randolph A. Clark added that the inventory build requires a few capital systems and a larger quantity of instruments, noting that finished instruments are already coming off the production line.

Ask Fintool Equity Research AI

Answer

Adam Sachs, Co-Founder and CEO, explained that the pivotal trial will commence as quickly as possible after the first clinical patient. He noted that the primary criteria for OUS site selection are the regulatory pathway and patient volume to ensure rapid enrollment. Regarding the V1.0 system, Sachs stated the final weeks are focused on running labs to gain confidence in system functionality and resolve any remaining issues before formal validation testing.

Ask Fintool Equity Research AI

Answer

CEO Jim Corbett affirmed that the cost-effectiveness and reduced length of stay for Cohealyx will be a 'very large deal' and a key adoption driver, similar to RECELL's success. He explained that for near-term VAC approval, the combination of preclinical data, early case studies, favorable pricing, and the consignment model would be the key drivers, rather than waiting for the full study results.

Ask Fintool Equity Research AI

Answer

CEO James Corbett affirmed that they remain just as optimistic about the TAM. He noted that the launch highlighted the need for more education at new centers, resulting in a longer VAC process and prompting the development of RECELL GO Mini for smaller wounds. Regarding the Dermal Matrix, he explained that competitors price around $14-$15/sq cm, and AVITA will price competitively while building clinical data. Animal studies suggest their matrix could be graft-ready in half the time of competitors, creating significant market potential.

Ask Fintool Equity Research AI

Answer

CEO Kevin Lobo described the ASC trend as being in the 'early innings,' providing a steady, long-term tailwind for multiple divisions. He stated that near-term M&A would focus on integrating Inari and adding tuck-ins within peripheral vascular, not expanding into broader cardiovascular markets.

Ask Fintool Equity Research AI

Answer

CEO Joaquin Duato explained that while large deals like Shockwave are outliers, the core strategy remains focused on smaller, value-creating bolt-on acquisitions, noting over 40 such deals in 2024. CFO Joseph Wolk added that the significant investments in Abiomed and Shockwave are performing well, with Abiomed growing 15% in 2024 and Shockwave delivering substantial growth, reinforcing their leadership in high-growth cardiovascular markets.

Ask Fintool Equity Research AI